TY - JOUR
T1 - Proceedings of the fifth international Molecular Pathological Epidemiology (MPE) meeting
AU - Yao, Song
AU - Campbell, Peter T.
AU - Ugai, Tomotaka
AU - Gierach, Gretchen
AU - Abubakar, Mustapha
AU - Adalsteinsson, Viktor
AU - Almeida, Jonas
AU - Brennan, Paul
AU - Chanock, Stephen
AU - Golub, Todd
AU - Hanash, Samir
AU - Harris, Curtis
AU - Hathaway, Cassandra A.
AU - Kelsey, Karl
AU - Landi, Maria Teresa
AU - Mahmood, Faisal
AU - Newton, Christina
AU - Quackenbush, John
AU - Rodig, Scott
AU - Schultz, Nikolaus
AU - Tearney, Guillermo
AU - Tworoger, Shelley S.
AU - Wang, Molin
AU - Zhang, Xuehong
AU - Garcia-Closas, Montserrat
AU - Rebbeck, Timothy R.
AU - Ambrosone, Christine B.
AU - Ogino, Shuji
N1 - Funding Information:
Dr. Scott Rodig receives research support from Bristol-Myers Squibb, Merck, KITE/Gilead, and Affimed. Dr. Rodig is on the SAB for Immunitas Therapeutics and has stock options in the company. Dr. Guillermo Tearney received sponsored research funding from Xsphera Biosciences. Dr. Karl Kelsey is a founder of Cellintec which had no role in this research. No other authors declare conflicts of interest related to the work presented here.
Funding Information:
The work presented at the meeting and summarized in the proceedings were supported in part by the following funding sources: Drs. Mustapha Abubakar, Jonas Almeida, Stephen Chanock, Curtis Harris and Maria Teresa Landi- Intramural Research Program of the Division of Cancer Epidemiology and Genetics (DCEG) of the National Cancer Institute (NCI); Dr. Christine Ambrosone—U.S. National Institutes of Health (NIH) grant R01 CA225947 and Breast Cancer Research Foundation; Dr. Samir Hanash—NCI, the MD Anderson Moonshot Program and the PanCan Foundation; Dr. Karl Kelsey—NIH R01 CA216265, R01 CA253976, 2018 AACR-Johnson & Johnson Lung Cancer Innovation Science (18‐90‐52‐MICH), CDMRP/Department of Defense (W81XWH-20–1-0778), NIGMS (P20 GM1044168299), P30 CA168524, P20 GM130423, P20 GM103428, R01 CA207360, P50 CA097257, and T35 HL094308; Dr. Shuji Ogino—NIH grant R35 CA197735; Dr. John Quackenbush—NIH R35 CA220523 and U24 CA231846; Dr. Scott Rodig—Bristol-Myers Squibb, Merck, KITE/Gilead, and a T32 NIH training grant provided to the Department of Pathology of Brigham and Women's Hospital; Dr. Nikolaus Schultz—NCI P30 CA008748, U24 CA220457, R01 CA204749, the Fund for Innovation in Cancer Informatics (ICI), the Robertson Foundation, a Prostate Cancer Foundation Challenge Award, and the Marie-Josée and Henry R. Kravis Center for Molecular Oncology; Dr. Guillermo Tearney—NIH R01 CA265742; Dr. Shelley Tworoger—NIH P01 CA87969, U01 CA176726, UM1 CA186107, the James and Esther King Biomedical Research Program of the Florida Department of Health 9JK02, and the Biostatistics and Bioinformatics Shared Resource at Moffitt Cancer Center.
Publisher Copyright:
© 2022, The Author(s), under exclusive licence to Springer Nature Switzerland AG.
PY - 2022/8
Y1 - 2022/8
N2 - Cancer heterogeneities hold the key to a deeper understanding of cancer etiology and progression and the discovery of more precise cancer therapy. Modern pathological and molecular technologies offer a powerful set of tools to profile tumor heterogeneities at multiple levels in large patient populations, from DNA to RNA, protein and epigenetics, and from tumor tissues to tumor microenvironment and liquid biopsy. When coupled with well-validated epidemiologic methodology and well-characterized epidemiologic resources, the rich tumor pathological and molecular tumor information provide new research opportunities at an unprecedented breadth and depth. This is the research space where Molecular Pathological Epidemiology (MPE) emerged over a decade ago and has been thriving since then. As a truly multidisciplinary field, MPE embraces collaborations from diverse fields including epidemiology, pathology, immunology, genetics, biostatistics, bioinformatics, and data science. Since first convened in 2013, the International MPE Meeting series has grown into a dynamic and dedicated platform for experts from these disciplines to communicate novel findings, discuss new research opportunities and challenges, build professional networks, and educate the next-generation scientists. Herein, we share the proceedings of the Fifth International MPE meeting, held virtually online, on May 24 and 25, 2021. The meeting consisted of 21 presentations organized into the three main themes, which were recent integrative MPE studies, novel cancer profiling technologies, and new statistical and data science approaches. Looking forward to the near future, the meeting attendees anticipated continuous expansion and fruition of MPE research in many research fronts, particularly immune-epidemiology, mutational signatures, liquid biopsy, and health disparities.
AB - Cancer heterogeneities hold the key to a deeper understanding of cancer etiology and progression and the discovery of more precise cancer therapy. Modern pathological and molecular technologies offer a powerful set of tools to profile tumor heterogeneities at multiple levels in large patient populations, from DNA to RNA, protein and epigenetics, and from tumor tissues to tumor microenvironment and liquid biopsy. When coupled with well-validated epidemiologic methodology and well-characterized epidemiologic resources, the rich tumor pathological and molecular tumor information provide new research opportunities at an unprecedented breadth and depth. This is the research space where Molecular Pathological Epidemiology (MPE) emerged over a decade ago and has been thriving since then. As a truly multidisciplinary field, MPE embraces collaborations from diverse fields including epidemiology, pathology, immunology, genetics, biostatistics, bioinformatics, and data science. Since first convened in 2013, the International MPE Meeting series has grown into a dynamic and dedicated platform for experts from these disciplines to communicate novel findings, discuss new research opportunities and challenges, build professional networks, and educate the next-generation scientists. Herein, we share the proceedings of the Fifth International MPE meeting, held virtually online, on May 24 and 25, 2021. The meeting consisted of 21 presentations organized into the three main themes, which were recent integrative MPE studies, novel cancer profiling technologies, and new statistical and data science approaches. Looking forward to the near future, the meeting attendees anticipated continuous expansion and fruition of MPE research in many research fronts, particularly immune-epidemiology, mutational signatures, liquid biopsy, and health disparities.
KW - Immuno-epidemiology
KW - Meeting proceedings
KW - Meeting report
KW - Meeting summary
KW - Molecular pathological epidemiology
UR - http://www.scopus.com/inward/record.url?scp=85132948451&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85132948451&partnerID=8YFLogxK
U2 - 10.1007/s10552-022-01594-7
DO - 10.1007/s10552-022-01594-7
M3 - Article
C2 - 35759080
AN - SCOPUS:85132948451
VL - 33
SP - 1107
EP - 1120
JO - Cancer Causes and Control
JF - Cancer Causes and Control
SN - 0957-5243
IS - 8
ER -